Global Alpha- Antitrypsin Deficiency Treatment Market Insights, Research Forecast to 2025

Published On: Jul 2019

Format: PDF

Publisher: QY Research

Pages: 128

Report ID: 4224

The global Alpha- Antitrypsin Deficiency Treatment market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Alpha- Antitrypsin Deficiency Treatment market based on company, product type, end user and key regions.

This report studies the global market size of Alpha- Antitrypsin Deficiency Treatment in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Alpha- Antitrypsin Deficiency Treatment in these regions.
This research report categorizes the global Alpha- Antitrypsin Deficiency Treatment market by top players/brands, region, type and end user. This report also studies the global Alpha- Antitrypsin Deficiency Treatment market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Adverum Biotechnologies, Inc.
Alnylam Pharmaceuticals, Inc.
Applied Genetic Technologies Corporation
Arrowhead Pharmaceuticals, Inc.
Carolus Therapeutics, Inc.
Cevec Pharmaceuticals GmbH
Dicerna Pharmaceuticals, Inc.
Digna Biotech, S.L.
Editas Medicine, Inc.
Grifols, S.A.
Inhibrx
Intellia Therapeutics, Inc.
International Stem Cell Corporation
Ionis Pharmaceuticals, Inc.
Kamada Ltd.
Polyphor Ltd.
ProMetic Life Sciences Inc.
rEVO Biologics, Inc.
Sangamo BioSciences, Inc.

Market size by Product
CT-2009
POL-6014
ARO-AAT
ALNAAT-02
Others
Market size by End User
Clinic
Hospital
Others

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Alpha- Antitrypsin Deficiency Treatment market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Alpha- Antitrypsin Deficiency Treatment market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Alpha- Antitrypsin Deficiency Treatment companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Alpha- Antitrypsin Deficiency Treatment submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Alpha- Antitrypsin Deficiency Treatment are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Alpha- Antitrypsin Deficiency Treatment market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Study Coverage
1.1 Alpha- Antitrypsin Deficiency Treatment Product
1.2 Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
1.4.1 Global Alpha- Antitrypsin Deficiency Treatment Market Size Growth Rate by Product
1.4.2 CT-2009
1.4.3 POL-6014
1.4.4 ARO-AAT
1.4.5 ALNAAT-02
1.4.6 Others
1.5 Market by End User
1.5.1 Global Alpha- Antitrypsin Deficiency Treatment Market Size Growth Rate by End User
1.5.2 Clinic
1.5.3 Hospital
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Alpha- Antitrypsin Deficiency Treatment Market Size
2.1.1 Global Alpha- Antitrypsin Deficiency Treatment Revenue 2014-2025
2.1.2 Global Alpha- Antitrypsin Deficiency Treatment Sales 2014-2025
2.2 Alpha- Antitrypsin Deficiency Treatment Growth Rate by Regions
2.2.1 Global Alpha- Antitrypsin Deficiency Treatment Sales by Regions
2.2.2 Global Alpha- Antitrypsin Deficiency Treatment Revenue by Regions

3 Breakdown Data by Manufacturers
3.1 Alpha- Antitrypsin Deficiency Treatment Sales by Manufacturers
3.1.1 Alpha- Antitrypsin Deficiency Treatment Sales by Manufacturers
3.1.2 Alpha- Antitrypsin Deficiency Treatment Sales Market Share by Manufacturers
3.1.3 Global Alpha- Antitrypsin Deficiency Treatment Market Concentration Ratio (CR5 and HHI)
3.2 Alpha- Antitrypsin Deficiency Treatment Revenue by Manufacturers
3.2.1 Alpha- Antitrypsin Deficiency Treatment Revenue by Manufacturers (2014-2019)
3.2.2 Alpha- Antitrypsin Deficiency Treatment Revenue Share by Manufacturers (2014-2019)
3.3 Alpha- Antitrypsin Deficiency Treatment Price by Manufacturers
3.4 Alpha- Antitrypsin Deficiency Treatment Manufacturing Base Distribution, Product Types
3.4.1 Alpha- Antitrypsin Deficiency Treatment Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Alpha- Antitrypsin Deficiency Treatment Product Type
3.4.3 Date of International Manufacturers Enter into Alpha- Antitrypsin Deficiency Treatment Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product
4.1 Global Alpha- Antitrypsin Deficiency Treatment Sales by Product
4.2 Global Alpha- Antitrypsin Deficiency Treatment Revenue by Product
4.3 Alpha- Antitrypsin Deficiency Treatment Price by Product

5 Breakdown Data by End User
5.1 Overview
5.2 Global Alpha- Antitrypsin Deficiency Treatment Breakdown Data by End User

6 North America
6.1 North America Alpha- Antitrypsin Deficiency Treatment by Countries
6.1.1 North America Alpha- Antitrypsin Deficiency Treatment Sales by Countries
6.1.2 North America Alpha- Antitrypsin Deficiency Treatment Revenue by Countries
6.1.3 United States
6.1.4 Canada
6.1.5 Mexico
6.2 North America Alpha- Antitrypsin Deficiency Treatment by Product
6.3 North America Alpha- Antitrypsin Deficiency Treatment by End User

7 Europe
7.1 Europe Alpha- Antitrypsin Deficiency Treatment by Countries
7.1.1 Europe Alpha- Antitrypsin Deficiency Treatment Sales by Countries
7.1.2 Europe Alpha- Antitrypsin Deficiency Treatment Revenue by Countries
7.1.3 Germany
7.1.4 France
7.1.5 UK
7.1.6 Italy
7.1.7 Russia
7.2 Europe Alpha- Antitrypsin Deficiency Treatment by Product
7.3 Europe Alpha- Antitrypsin Deficiency Treatment by End User

8 Asia Pacific
8.1 Asia Pacific Alpha- Antitrypsin Deficiency Treatment by Countries
8.1.1 Asia Pacific Alpha- Antitrypsin Deficiency Treatment Sales by Countries
8.1.2 Asia Pacific Alpha- Antitrypsin Deficiency Treatment Revenue by Countries
8.1.3 China
8.1.4 Japan
8.1.5 Korea
8.1.6 India
8.1.7 Australia
8.1.8 Indonesia
8.1.9 Malaysia
8.1.10 Philippines
8.1.11 Thailand
8.1.12 Vietnam
8.1.13 Singapore
8.2 Asia Pacific Alpha- Antitrypsin Deficiency Treatment by Product
8.3 Asia Pacific Alpha- Antitrypsin Deficiency Treatment by End User

9 Central & South America
9.1 Central & South America Alpha- Antitrypsin Deficiency Treatment by Countries
9.1.1 Central & South America Alpha- Antitrypsin Deficiency Treatment Sales by Countries
9.1.2 Central & South America Alpha- Antitrypsin Deficiency Treatment Revenue by Countries
9.1.3 Brazil
9.2 Central & South America Alpha- Antitrypsin Deficiency Treatment by Product
9.3 Central & South America Alpha- Antitrypsin Deficiency Treatment by End User

10 Middle East and Africa
10.1 Middle East and Africa Alpha- Antitrypsin Deficiency Treatment by Countries
10.1.1 Middle East and Africa Alpha- Antitrypsin Deficiency Treatment Sales by Countries
10.1.2 Middle East and Africa Alpha- Antitrypsin Deficiency Treatment Revenue by Countries
10.1.3 GCC Countries
10.1.4 Turkey
10.1.5 Egypt
10.1.6 South Africa
10.2 Middle East and Africa Alpha- Antitrypsin Deficiency Treatment by Product
10.3 Middle East and Africa Alpha- Antitrypsin Deficiency Treatment by End User

11 Company Profiles
11.1 Adverum Biotechnologies, Inc.
11.1.1 Adverum Biotechnologies, Inc. Company Details
11.1.2 Company Business Overview
11.1.3 Adverum Biotechnologies, Inc. Alpha- Antitrypsin Deficiency Treatment Sales, Revenue and Gross Margin (2014-2019)
11.1.4 Adverum Biotechnologies, Inc. Alpha- Antitrypsin Deficiency Treatment Products Offered
11.1.5 Adverum Biotechnologies, Inc. Recent Development
11.2 Alnylam Pharmaceuticals, Inc.
11.2.1 Alnylam Pharmaceuticals, Inc. Company Details
11.2.2 Company Business Overview
11.2.3 Alnylam Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Sales, Revenue and Gross Margin (2014-2019)
11.2.4 Alnylam Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Products Offered
11.2.5 Alnylam Pharmaceuticals, Inc. Recent Development
11.3 Applied Genetic Technologies Corporation
11.3.1 Applied Genetic Technologies Corporation Company Details
11.3.2 Company Business Overview
11.3.3 Applied Genetic Technologies Corporation Alpha- Antitrypsin Deficiency Treatment Sales, Revenue and Gross Margin (2014-2019)
11.3.4 Applied Genetic Technologies Corporation Alpha- Antitrypsin Deficiency Treatment Products Offered
11.3.5 Applied Genetic Technologies Corporation Recent Development
11.4 Arrowhead Pharmaceuticals, Inc.
11.4.1 Arrowhead Pharmaceuticals, Inc. Company Details
11.4.2 Company Business Overview
11.4.3 Arrowhead Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Sales, Revenue and Gross Margin (2014-2019)
11.4.4 Arrowhead Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Products Offered
11.4.5 Arrowhead Pharmaceuticals, Inc. Recent Development
11.5 Carolus Therapeutics, Inc.
11.5.1 Carolus Therapeutics, Inc. Company Details
11.5.2 Company Business Overview
11.5.3 Carolus Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Sales, Revenue and Gross Margin (2014-2019)
11.5.4 Carolus Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Products Offered
11.5.5 Carolus Therapeutics, Inc. Recent Development
11.6 Cevec Pharmaceuticals GmbH
11.6.1 Cevec Pharmaceuticals GmbH Company Details
11.6.2 Company Business Overview
11.6.3 Cevec Pharmaceuticals GmbH Alpha- Antitrypsin Deficiency Treatment Sales, Revenue and Gross Margin (2014-2019)
11.6.4 Cevec Pharmaceuticals GmbH Alpha- Antitrypsin Deficiency Treatment Products Offered
11.6.5 Cevec Pharmaceuticals GmbH Recent Development
11.7 Dicerna Pharmaceuticals, Inc.
11.7.1 Dicerna Pharmaceuticals, Inc. Company Details
11.7.2 Company Business Overview
11.7.3 Dicerna Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Sales, Revenue and Gross Margin (2014-2019)
11.7.4 Dicerna Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Products Offered
11.7.5 Dicerna Pharmaceuticals, Inc. Recent Development
11.8 Digna Biotech, S.L.
11.8.1 Digna Biotech, S.L. Company Details
11.8.2 Company Business Overview
11.8.3 Digna Biotech, S.L. Alpha- Antitrypsin Deficiency Treatment Sales, Revenue and Gross Margin (2014-2019)
11.8.4 Digna Biotech, S.L. Alpha- Antitrypsin Deficiency Treatment Products Offered
11.8.5 Digna Biotech, S.L. Recent Development
11.9 Editas Medicine, Inc.
11.9.1 Editas Medicine, Inc. Company Details
11.9.2 Company Business Overview
11.9.3 Editas Medicine, Inc. Alpha- Antitrypsin Deficiency Treatment Sales, Revenue and Gross Margin (2014-2019)
11.9.4 Editas Medicine, Inc. Alpha- Antitrypsin Deficiency Treatment Products Offered
11.9.5 Editas Medicine, Inc. Recent Development
11.10 Grifols, S.A.
11.10.1 Grifols, S.A. Company Details
11.10.2 Company Business Overview
11.10.3 Grifols, S.A. Alpha- Antitrypsin Deficiency Treatment Sales, Revenue and Gross Margin (2014-2019)
11.10.4 Grifols, S.A. Alpha- Antitrypsin Deficiency Treatment Products Offered
11.10.5 Grifols, S.A. Recent Development
11.11 Inhibrx
11.12 Intellia Therapeutics, Inc.
11.13 International Stem Cell Corporation
11.14 Ionis Pharmaceuticals, Inc.
11.15 Kamada Ltd.
11.16 Polyphor Ltd.
11.17 ProMetic Life Sciences Inc.
11.18 rEVO Biologics, Inc.
11.19 Sangamo BioSciences, Inc.

12 Future Forecast
12.1 Alpha- Antitrypsin Deficiency Treatment Market Forecast by Regions
12.1.1 Global Alpha- Antitrypsin Deficiency Treatment Sales Forecast by Regions 2019-2025
12.1.2 Global Alpha- Antitrypsin Deficiency Treatment Revenue Forecast by Regions 2019-2025
12.2 Alpha- Antitrypsin Deficiency Treatment Market Forecast by Product
12.2.1 Global Alpha- Antitrypsin Deficiency Treatment Sales Forecast by Product 2019-2025
12.2.2 Global Alpha- Antitrypsin Deficiency Treatment Revenue Forecast by Product 2019-2025
12.3 Alpha- Antitrypsin Deficiency Treatment Market Forecast by End User
12.4 North America Alpha- Antitrypsin Deficiency Treatment Forecast
12.5 Europe Alpha- Antitrypsin Deficiency Treatment Forecast
12.6 Asia Pacific Alpha- Antitrypsin Deficiency Treatment Forecast
12.7 Central & South America Alpha- Antitrypsin Deficiency Treatment Forecast
12.8 Middle East and Africa Alpha- Antitrypsin Deficiency Treatment Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Alpha- Antitrypsin Deficiency Treatment Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer